ALNY PE Ratio & Valuation, Is ALNY Overvalued

Historical Valuation

Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.01 is considered Undervalued compared with the five-year average of -44.18. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 373.72 to 571.05 according to relative valuation method. Compared to the current price of 322.69 USD , Alnylam Pharmaceuticals Inc By Undervalued By 13.65%.

Relative Value

Fair Zone

373.72-571.05

Current Price：322.69

13.65%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Alnylam Pharmaceuticals Inc (ALNY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Alnylam Pharmaceuticals Inc (ALNY) has a current Price-to-Book (P/B) ratio of 225.48. Compared to its 3-year average P/B ratio of -1125.24, the current P/B ratio is approximately -120.04% higher. Relative to its 5-year average P/B ratio of -666.20, the current P/B ratio is about -133.85% higher. Alnylam Pharmaceuticals Inc (ALNY) has a Forward Free Cash Flow (FCF) yield of approximately 0.42%. Compared to its 3-year average FCF yield of -0.31%, the current FCF yield is approximately -235.77% lower. Relative to its 5-year average FCF yield of -1.54%, the current FCF yield is about -127.17% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ALNY competitors is 11.11, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY.O) exhibits a P/S ratio of 10.01, which is -9.89% above the industry average. Given its robust revenue growth of 84.95%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ALNY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ALNY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ALNY currently overvalued or undervalued?

Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.01 is considered Undervalued compared with the five-year average of -44.18. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 373.72 to 571.05 according to relative valuation method. Compared to the current price of 322.69 USD, Alnylam Pharmaceuticals Inc is Undervalued By 13.65%.

What is Alnylam Pharmaceuticals Inc (ALNY) fair value?

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between 373.72 to 571.05 according to relative valuation method.

How does ALNY's valuation metrics compare to the industry average?

The average P/S ratio for ALNY's competitors is 11.11, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of 10.01, which is -9.89% above the industry average. Given its robust revenue growth of 84.95%, this premium appears sustainable.

What is the current P/B ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Mar 11 2026?

As of Mar 11 2026, Alnylam Pharmaceuticals Inc (ALNY) has a P/B ratio of 225.48. This indicates that the market values ALNY at 225.48 times its book value.

What is the current FCF Yield for Alnylam Pharmaceuticals Inc (ALNY) as of Mar 11 2026?

As of Mar 11 2026, Alnylam Pharmaceuticals Inc (ALNY) has a FCF Yield of 0.42%. This means that for every dollar of Alnylam Pharmaceuticals Inc's market capitalization, the company generates 0.42 cents in free cash flow.

What is the current Forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Mar 11 2026?

As of Mar 11 2026, Alnylam Pharmaceuticals Inc (ALNY) has a Forward P/E ratio of 60.41. This means the market is willing to pay $60.41 for every dollar of Alnylam Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Mar 11 2026?

As of Mar 11 2026, Alnylam Pharmaceuticals Inc (ALNY) has a Forward P/S ratio of 10.01. This means the market is valuing ALNY at $10.01 for every dollar of expected revenue over the next 12 months.

ALNY Valuation